Keyphrases
Laser Immunotherapy
100%
Laser Irradiation
63%
Metastatic Cancer
60%
Glycated chitosan
50%
Multi-walled Carbon Nanotubes (MWCNTs)
41%
Anti-tumor Response
33%
Modified Carbon Nanotubes
33%
Rat Mammary Tumors
31%
Mammary Tumor Models
31%
Immune Response
20%
Immunological Response
19%
Cancer Patients
19%
Photothermal Effect
18%
Cyclophosphamide
17%
ALA-PDT
15%
Antitumor Effect
15%
Laser-assisted
15%
DC Vaccine
15%
Dendritic Cell Vaccine
15%
Apoptotic Cells
15%
Chemotherapy Resistance
15%
Skin Squamous Cell Carcinoma
15%
Metastatic Papillary Thyroid Carcinoma
15%
Green Solutions
15%
Diode Laser
15%
Interstitial Laser
15%
Cancer Cell Migration
15%
Gold Nanorods
15%
Indocyanine Green
15%
Papillary Thyroid Cancer
15%
Neoplasms
15%
Immunogenic
15%
Clinical Effect
15%
Immunological Stimulation
15%
Primary Tumor
14%
Photodynamic Therapy
13%
Treatment Group
12%
Melanoma
11%
Tumor
11%
T Cells
11%
Solid Tumors
11%
Immunoadjuvant
10%
Late-stage Breast Cancer
10%
Metastatic Tumor
10%
Cancer Cells
10%
Tumor-bearing Rats
9%
Immunological Stimulant
9%
Imiquimod
7%
T Cell Response
7%
Dendritic Cells
7%
Medicine and Dentistry
Neoplasm
55%
Immunotherapy
35%
Carbon Nanotube
33%
Tumor Model
31%
Breast Tumor
31%
Metastatic Carcinoma
29%
Single Walled Nanotube
22%
Chitosan
22%
Primary Tumor
16%
Gold Nanorod
15%
Indocyanine Green
15%
Papillary Thyroid Cancer
15%
Chemotherapy
15%
Melanoma
15%
Photochemotherapy
15%
Solid Malignant Neoplasm
11%
T Cell
11%
Immunological Adjuvant
10%
T-Cell Response
7%
Imiquimod
7%
Tumor Immunity
7%
Cancer Cell
7%
Cancer Cell Line
7%
Dimethylbenz[a]anthracene
7%
Thyroid Cancer
6%
Thyroidectomy
6%
Neck Mass
6%
Nanomaterial
5%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
69%
Metastasis
63%
Neoplasm
58%
Melanoma
24%
Chemotherapy
18%
Chitosan
16%
Cyclophosphamide
15%
Alpha-Linolenic Acid
15%
Squamous Cell Skin Carcinoma
15%
Photodynamic Therapy
15%
Breast Tumor
15%
Tumor Model
15%
Carbon Nanotube
15%
Solid Malignant Neoplasm
14%
Breast Cancer
12%
Dendritic Cell Vaccine
11%
Malignant Neoplasm
11%
Primary Tumor
7%
Imiquimod
7%
Single Walled Nanotube
7%
Immunologic Adjuvant
7%
Aminolevulinic Acid
6%
Clinical Trial
5%